DGAP-News: Geratherm Medical AG: The international medical journal 'Stroke' published convincing results of a clinical trial conducted at the University Hospital Heidelberg, Germany
(firmenpresse) - DGAP-News: Geratherm Medical AG / Key word(s): Study
Geratherm Medical AG: The international medical journal 'Stroke'
published convincing results of a clinical trial conducted at the
University Hospital Heidelberg, Germany
08.08.2012 / 10:11
---------------------------------------------------------------------
Clinical Trial Substantiates Superiority of SRAclinic in the Detection of
Atrial fibrillation
The international medical journal 'Stroke' published convincing results
of a clinical trial conducted at the University Hospital Heidelberg,
Germany
SRAclinic shows significant superiority over standard procedures - 40
percent more patients with paroxysmal atrial fibrillation identified
Geratherm/apoplex, Pirmasens, 08. August 2012. Throughout Germany, in
France and Austria, more than 30 hospitals (stroke units) already use
successfully the fully automated ECG analysis for the detection of atrial
fibrillation SRAclinic (SRA = Stroke Risk Analysis), developed by the
apoplex medical technologies GmbH, Pirmasens (Germany). The medical journal
'Stroke', an official journal of the American Heart Association, just
published the results of a clinical trial, which proves a clear superiority
of SRAclinic* to the current standard procedures for the detection of
paroxysmal atrial fibrillation. This is of great importance especially for
those patients with strokes of unknown origin. Only the detection of atrial
fibrillation makes an adequate therapy with anticoagulating drugs possible
to reduce the risk for further strokes.
The publication in 'Stroke' is based on a prospective study conducted by
the principal investigator Prof. Dr. med. Roland Veltkamp, between March
2010 and January 2011 on approximately 500 patients at the stroke unit of
the University Hospital Heidelberg. The study compared the detection rate
of paroxysmal atrial fibrillation of SRAclinic with the current standard
procedure. The investigators succeeded in proofing superiority of SRAclinic
over the 24 hour long term ECG and the ECG monitoring without the automated
detection software in the identification of patients with paroxysmal atrial
fibrillation.
'SRAclinic has clearly proven it's superiority over the elaborate methods
used in our stroke unit to detect atrial fibrillation', states Prof. Dr.
med. Roland Veltkamp. 'After the analysis of the study results we changed
the routine diagnostic for the detection of paroxysmal atrial fibrillation
at our stroke unit with 20 beds completely to SRAclinic. The anyway
recorded ECG signals from the monitoring system at the stroke unit are
analysed by SRAclinic. 24 hour long term ECGs are only recorded in
exceptional cases which means a considerable relieve for our colleagues
from cardiology.'
This is the link to the online published abstract in 'stroke'.
http://stroke.ahajournals.org/content/early/2012/08/07/STROKEAHA.112.65495
4.abstract?sid=53a0663e-7a28-4fb7-b841-cb9dab80d5e0
The full paper can be accessed online on the internet page of 'stroke'
after registration.
'SRAclinic is well on the way to become the standard procedure for the
detection of paroxysmal atrial fibrillation in stroke units. In about 25
percent of all strokes in Germany the origin of the stroke cannot be
identified. A substantial part of these is assumed to be caused by
undetected paroxysmal atrial fibrillation, which increases the risk for
secondary strokes with worse consequences for the patients' states Albert
Hirtz, Managing Director of apoplex medical technologies GmbH. 'New methods
do not necessarily induce higher costs but can often reduce the current
costs - with benefits for the patients and the insurance companies.
SRAclinic is safe, reliable and a resource-efficient solution, as it uses
data from the monitoring system for the analysis' emphasizes Albert Hirtz
the economical advantages of SRAclinic.
Convincing Study Results
The objective of the study was a comparison of the two presently applied
standard procedures in stroke units, which are 24 hour long term ECG and
patient monitoring, with SRAclinic in relation to an identification of
patients with previously unknown paroxysmal atrial fibrillation. Patients
with ischemic stroke or TIA (transitional ischemic attack) were included in
the study. During their stay at the stroke unit, in 41 from 496 patients
paroxysmal atrial fibrillation was detected for the first time. 14 (34.1%)
patients were found with 24 ECG recordings, 27 (65.9%) with the continuous
bed side electrographic monitoring and 38 (92.7%) have been identified with
SRAclinic. That means, SRAclinic is able to increase the detection rate for
paroxysmal atrial fibrillation more than twofold compared to the widely
used 24 hour long term ECG recording.
Background information to SRAclinic
The fully automated Stroke Risk Analysis SRAclinic, developed by the
apoplex medical technologies GmbH, Pirmasens, for the detection of atrial
fibrillation is already used in the stroke units of more than 30 hospitals
in Germany, France and Austria.
SRAclinic is analysing the ECG data from the mandatory patient monitoring
or from long term ECG recordings. The analysis is based on a mathematical
algorithm which interprets deviations from the heart rate dynamics which
come along with atrial fibrillation. There is also a version for primary
prevention (SRAdoc und SRA24), which is offered to General practitioners.
Supplementary information about apoplex medical technologies
apoplex medical technologies GmbH was founded in 2004 in Pirmasens, in the
west of the Rhineland-Palatinate, and, within the field of medical
technology, specializes in new and innovative technological products for
the prevention of strokes throughout the world. The subsidiary of Geratherm
Medical AG focuses on easily applicable and efficient methods of patient
screening using medical-technical applications to prevent strokes and
vascular dementia. The SRA (Stroke Risk Analysis) procedure is the first
practicable screening method for paroxysmal atrial fibrillation. It is
available in versions for use in medical practices and stroke units.
apoplex medical technologies is supported by an extensive academic and
clinical network, which professionally supplements its own core competences
in the fields of mathematics, physics and medicine. Further information is
available at www.apoplexmedical.com.
Additional information
apoplex medical technologies GmbH
Albert Hirtz
Delaware Avenue 1 - 3
D-66953 Pirmasens
fon: +49/(0)6331/698998-0
fax: +49/(0)6331/698998-19
http://www.apoplexmedical.com
a.hirtz(at)apoplexmedical.com
End of Corporate News
---------------------------------------------------------------------
08.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Geratherm Medical AG
Fahrenheitstraße 1
98716 Geschwenda
Germany
Phone: +49 (0)36205 98-0
Fax: +49 (0)36205 98-1 15
E-mail: info(at)geratherm.com
Internet: www.geratherm.com
ISIN: DE0005495626
WKN: 549562
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
180850 08.08.2012
Themen in dieser Pressemitteilung:
geratherm-medical-ag-the-international-medical-journal-stroke-published-convincing-results-of-a-clinical-trial-conducted-at-the-university-hospital-heidelberg
germany
Unternehmensinformation / Kurzprofil:
Datum: 08.08.2012 - 10:11 Uhr
Sprache: Deutsch
News-ID 172567
Anzahl Zeichen: 7739
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 271 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Geratherm Medical AG: The international medical journal 'Stroke' published convincing results of a clinical trial conducted at the University Hospital Heidelberg, Germany"
steht unter der journalistisch-redaktionellen Verantwortung von
Geratherm Medical AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
